Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06255028Phase 1Active Not Recruiting

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Role: lead

NCT05336409Phase 1Terminated

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Role: lead

NCT05768269Recruiting

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Role: lead

All 3 trials loaded